OptiBiotix Health: Inside the Gut Health Gold Rush

The boom in weight-loss injections like Ozempic and Wegovy looks at first like a threat to a natural appetite product, but OptiBiotix has reframed it as an opportunity. The drugs work while you take them, but most users regain two-thirds of their lost weight within a year of stopping, and 58% quit within three months over cost or side-effects. That creates a large and growing pool of people who need a more sustainable, affordable way to keep the weight off.

SlimBiome, clinically shown to curb hunger and cravings, is being positioned as exactly that: a cheaper, side-effect-free natural option, and a way to prevent rebound weight gain after coming off the injections through an orally taken solution. SlimBiome has won awards for best weight management ingredient in Europe, Asia and the USA, and is stocked in well known stores such as Holland & Barrett and Dr Morepen (India). The market for GLP-1 alternatives is forecast to quadruple to $4.8bn by 2033, and major weight-management brands are already seeking clinically-backed ingredients to sit alongside the drugs, with OptiBiotix landing partners including Hydroxycut in the US (sold in Walmart) and OptiSlim in Australia (sold in Chemist Warehouse). The global traction demonstrates the size of demand for the solutions OptiBiotix provides.

For a decade OptiBiotix invested in building the hard stuff: a 50-patent IP portfolio, human clinical trials, on pack health claims, and manufacturing and distribution networks across the UK, US, India and Asia. That investment phase is now largely complete, and the focus has shifted to turning those assets into sales, margin and eventually profit.

The early evidence is encouraging: 2025 revenue rose 34% to £1.17m, gross profit jumped 85%, gross margins climbed from 38% to 53%, and the company booked a record £800k-plus of orders in the first weeks of 2026. Asia has been a big driver of these numbers with 17 products launched and 74 customer projects at various stages of development across six different countries. Crucially, each business unit (US, India, e-commerce and B2B) is now accountable for covering its own costs, and ingredient savings of up to 48% on its core product should lift margins further. The business is not profitable yet, and still posted a loss in 2025, but for the first time it has a clear, near-term route toward break-even rather than open-ended cash burn.

Two second-generation products sit largely uncredited by the market. The first is SweetBiotix, a natural sweet fibre protected by 25-plus patents. A 2025 enzyme breakthrough made it cheaper, purer and convertible from ordinary sugar, turning sugar producers from rivals into potential partners; DSM-Firmenich, one of several with development agreements in place, has forecast demand of more than 100,000 tonnes a year. At an investor tasting in June 2026, attendees compared it to sugar and unanimously found it clean, sweet, and sweeter still. The second is microbiome modulators: prebiotics that selectively feed specific gut microbes, letting users boost beneficial bacteria and crowd out harmful ones. The potential runs from making drugs safer and more effective to influencing diseases thought to begin in the gut. If the microbiome really is the future of healthcare, precision tools like these are how that future gets built.

On top of this, OptiBiotix holds equity stakes in two microbiome businesses it created and floated separately, ProBiotix Health and SkinBioTherapeutics, worth £6.45m at the end of 2025. It has already raised £7.81m by selling SkinBioTherapeutics shares over the years, and returned £10.25m to shareholders by distributing ProBiotix shares when it listed in 2022. These assets provide a financing source to fund the business without always turning to shareholders, though the value moves with the two companies' share prices.

• Order delivery and margin proof points: The record 2026 order book (£800k-plus booked by late January) converting into delivered, higher-margin revenue would validate the turnaround. Ingredient cost reductions of up to 48% on SlimBiome should show through in H2 2026 margins.
  
  

• New US and Asian partners: Fresh launches like Hydroxycut Hunger Control, a first order from Taiwan's Meelung Trading, and strong interest at trade show SupplySide Global all point to a widening customer base. More named partners would ease concentration concerns.

• A SweetBiotix commercial launch: OptiBiotix already has development and scale-up agreements in place, including with DSM-Firmenich. The catalyst investors are waiting for is the step up to a binding commercial supply deal, when milestone income gives way to royalties on real sales.
  
  

• WellBiome NHS study read-out: The Hull University Teaching Hospital trial on cardiac-surgery outcomes could, if successful, open a path to WellBiome becoming a standard of care.

• Group profitability and divisional break-even: Each business unit covering its costs and the group turning profitable would re-rate a story long valued only on potential.
  
  

• Monetising or realising listed stakes: Crystallising value from the ProBiotix and SkinBioTherapeutics holdings, via sale or special return, could reward shareholders directly. M&A interest across the weight-management space (Danone buying Huel) highlights the appeal of IP-backed brands.

Around 73% of revenue now comes from overseas, which shows the international model is working. However, the two markets management sees as most strategically important, the US and India, have yet to deliver on their full potential and still lean on a limited number of customers. Losing or seeing reduced orders from one of these key partners would hit the growth story hardest where it matters most, an effect amplified by the fact that several partners are themselves restructuring. Management is actively widening the customer base, but until those flagship markets broaden and mature, progress stays tied to a handful of relationships in the competitive, high-churn weight-management sector.

SweetBiotix is central to the long-term story, yet it has been close to commercialisation for some time. The 2025 enzyme breakthrough is real progress, and DSM-Firmenich's preliminary 100,000-tonne forecast is eye-catching, but converting samples and material-transfer agreements into binding, revenue-generating contracts is not guaranteed. Milestone payments from partner agreements have delivered over £750k of SweetBiotix income to OptiBiotix in recent years, but the full launch of commercial products will be the key signal that the potential is being realised. Larger partners move slowly, and scale-up was already delayed by the DSM/Firmenich merger. If a meaningful deal keeps slipping, the market may continue to ascribe little value to the IP.

OptiBiotix remains loss-making, with an operating loss of £2.7m in 2025 and year-end cash of just £1.04m against an annual operating cost base near £2.7m. The shares trade well below historic levels. To fund itself the company has at times issued new shares and sold tranches of its listed holdings, including £787,000 raised from SkinBioTherapeutics share sales in early 2026. Management points to genuine mitigations, with marketing costs down 78%, rising sales, no debt, and the ability to sell investments if needed, and the auditors signed off the accounts on a going-concern basis. Even so, a small cash balance against a business still burning cash leaves little headroom if the 2026 recovery underwhelms or a key partner stumbles.